Home - Cabometyx Norway

Select an indication for CABOMETYX® (cabozantinib)

CABOMETYX® is a small molecule that inhibits multiple receptor tyrosine kinases implicated in tumour growth and angiogenesis, pathologic bone remodelling, drug resistance and metastatic progression of cancer.¹

Felleskatalogen

Renal Cell Carcinoma

CABOMETYX^®(cabozantinib) for the treatment of advanced renal cell carcinoma:¹

• In treatment-naïve adults with intermediate or poor risk

• In adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

^{1. CABOMETYX® Summary of Product Characteristics.} View the CABOMETYX®SmPC

© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the Norway Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Cabometyx in Europe

Select an indication for CABOMETYX® (cabozantinib)

Renal Cell Carcinoma

Welcome to Cabometyx.no website. This website is intended for Norway Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.